Drugs in MeSH Category Glycoside Hydrolase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	PRECOSE	acarbose	TABLET;ORAL	020482-001	Sep 6, 1995		DISCN	Yes	No
Watson Labs	ACARBOSE	acarbose	TABLET;ORAL	077532-001	May 7, 2008	AB	RX	No	No
Somerset Theraps Llc	ACARBOSE	acarbose	TABLET;ORAL	091343-003	Oct 17, 2013	AB	RX	No	No
Somerset Theraps Llc	ACARBOSE	acarbose	TABLET;ORAL	091343-002	Oct 17, 2013	AB	RX	No	No

Market Dynamics and Patent Landscape for NLM MeSH Class: Glycoside Hydrolase Inhibitors (Global Exclusivity, Patent Expiry, and Generic Entry Risk)

Last updated: June 25, 2026

Executive summary

Glycoside hydrolase inhibitors are a niche but high-value therapeutic area dominated by a small number of branded enzyme or substrate-disruption drugs used in lysosomal storage disorders (LSDs), metabolic diseases, and select inflammatory or neurologic indications. Patent estates are typically concentrated in (1) active ingredient claims (often limited by early filings), (2) formulation and process patents that extend enforceability around oral solid dosage forms and long-term stability requirements, and (3) method-of-use claims supporting specific indication or titration regimens. Commercial exposure is concentrated in early-market entrants with limited follow-on product differentiation, creating windows where Paragraph IV litigation and “authorized generic” strategies can materially alter revenue trajectories.

What patents protect glycoside hydrolase inhibitors (active ingredient, formulation, and method-of-use)?

In most glycoside hydrolase inhibitor portfolios, the core patent estate is split across active ingredient, composition/formulation, and method-of-use claims. In practice, the most litigation-relevant patents are usually composition-of-matter and key “how to use” patents tied to approved indications, dosing schedules, or patient selection criteria.

Which MeSH “Glycoside Hydrolase Inhibitors” molecules drive exclusivity?

The MeSH class covers inhibitor chemotypes across glycosidases (lysosomal beta-glucosidases, alpha-glucosidases, alpha-galactosidases, etc.). The market’s high-impact commercial products tend to cluster in LSDs where oral small molecules are paired with diagnostic and disease severity monitoring, creating room for regimen-specific method-of-use claims.

Typical patent claim categories in this therapeutic class

1. Composition of matter (active ingredient and salts)
   Often filed early, with statutory term and extensions dependent on regulatory delay and granted patent scope.
2. Formulation patents (tablet/capsule, solid state, stabilizers)
   Common for oral inhibitors requiring moisture control, polymorph control, or extended shelf-life. These can meaningfully affect generic bioequivalence and manufacturability.
3. Process patents (API synthesis routes, purification, crystallization)
   Often litigated when a generic attempts to copy a manufacturing process or when impurities and polymorph control affect product stability and regulatory compliance.
4. Method-of-use patents (indication, dose, titration, combination)
   Particularly common when approvals include controlled dosing escalation, patient subgroups, or combination therapy language.

How many patents cover a typical glycosidase inhibitor drug?

Across branded portfolios in this class, the enforcing family count often ranges from low double digits to mid double digits once you account for salts, polymorphs, key intermediates, and formulation/process continuations. The enforceable subset for litigation is usually a smaller subset: those with granted claims in the relevant jurisdictions and those listed (or referenced) in Orange Book equivalents for the approved product.

How strong is the patent estate for glycoside hydrolase inhibitors?

Patent strength in this class is determined less by raw family count and more by (1) claim breadth of composition/formulation and (2) enforceability at the US district court level or under EMA/national validation. Method-of-use claims can be strong where claim language tracks the label, but they are more vulnerable if generics can design around by using a different dosing regimen or patient population.

Key strength drivers

• Granted, not just filed claims: Enforceability hinges on issued claims with surviving prosecution histories.
• Continuations and divisional strategy: Follow-on claim diversification extends enforcement against design-arounds.
• Polymorph and solid-state control: If formulation patents are claim-dense and include narrow but specific solid-state features, generic development must meet additional constraints.
• Process “knockouts”: If the active impurity profile is tied to a claimed purification step, generics may face higher development friction or require additional BE/CMC data.

When does exclusivity end for glycoside hydrolase inhibitors (US, EU, and global timeline)?

Exclusivity timelines usually break into two layers: regulatory exclusivity (data and market exclusivity) and patent term. Market exclusivity (and data exclusivity) can delay generic approval even when patents are not fully controlling, while patents determine launch timing under Hatch-Waxman or national equivalents.

US: regulatory exclusivity vs patent expiration

• Hatch-Waxman links ANDA timing to Orange Book-listed patents.
• 510(k)/505(b)(2) pathways can differ in listing triggers, changing the “entry fence” even if therapeutic class is the same.
• Orphan drug exclusivity is common in LSDs and can materially extend non-patent exclusivity windows when applicable.

EU: SPC and national patent term extensions

• EU market authorization can be followed by Supplementary Protection Certificates (SPC) that extend patent life beyond the base patent term.
• Enforcement depends on national validation and local injunction standards.

Typical market “cliff” dynamics

When the last listed patent (and regulatory exclusivity) fall, generic erosion can occur quickly unless:

• formulation-specific patents remain in force,
• a settlement agreement delays the launch,
• authorized generics are pre-positioned,
• or product-specific manufacturing patents block CMC acceptance.

What generic entry risks exist for glycoside hydrolase inhibitors (ANDA, Paragraph IV, biosimilar analogs)?

Generic entry risk is highest where US Orange Book patent listing is thin, where method-of-use claims can be designed around, or where formulation patents do not cover the generic product’s solid-state attributes. Paragraph IV challenges are most likely against composition-of-matter or key formulation patents that prevent immediate launch.

Paragraph IV litigation patterns to expect in this class

• Challenging composition-of-matter patents when the generic believes scope is narrow or prosecution history estops broad interpretation.
• Challenging formulation patents using alternative polymorph/salt forms that still meet bioequivalence.
• Settlement-driven delayed launches common where infringement risk is credible and generic economics depend on predictable launch dates.

Biosimilar risk?

These drugs are generally small-molecule inhibitors, so the biosimilar framework is not the main risk channel. The relevant parallel risk is authorized generic and follow-on NDA (new formulation, dosing form, or label expansion) rather than biosimilars.

What formulations are protected by patents for glycoside hydrolase inhibitors?

Formulation IP is often the most actionable in generic development because it can influence acceptable polymorph selection, excipient systems, and manufacturing controls that drive CMC costs and BE success.

Common formulation IP targets

• Polymorphs and solvates of the free base/salt form
• Stable solid forms with specified melting points, XRPD peaks, or hygroscopicity targets
• Film coating or immediate release vs extended release structural claims
• Moisture-barrier packaging claims are less common but can appear in secondary claims

Why formulation patents matter for generic timing

Even when the active ingredient patent expires, a generic cannot launch if:

• the formulation patent is still active and covers the product’s covered attributes,
• or settlement delays launch.

How do glycoside hydrolase inhibitors compare in patent estates vs competitors in the same indication?

Within a given LSD or disease area, the competitor set is usually defined by mechanism (different glycosidase targets), delivery (oral vs other), and dosing regimen. IP typically separates into two “lanes”:

1. Mechanism-first estates (active ingredient and method-of-use)
2. Product-first estates (solid-state, dosage form, and process)

Practical competitive implications

• If the leading drug’s patent estate is anchored in active ingredient claims, competitors face a longer licensing horizon.
• If the leading drug’s estate is anchored in formulation patents, competitors can design around with different polymorphs or manufacturing routes, sometimes reducing enforceability risk but increasing development cost.

Which companies are challenging patents on glycoside hydrolase inhibitors?

A defensible, litigation-ready list requires linkage between specific drug labels and Orange Book patent records, plus PACER/RECAP and FDA Paragraph IV notices. This dataset is not provided in the prompt, so a complete and accurate company-by-company challenge map cannot be produced.

What patent litigation affects glycoside hydrolase inhibitors (settlements, injunctions, and launch delays)?

A complete assessment requires:

• drug-level patent listing (US Orange Book or national equivalents),
• docketed litigation outcomes,
• and settlement terms that specify final launch dates or “at-risk” entry restrictions.

The prompt provides only a MeSH class description and does not specify which products, jurisdictions, or docketed cases. A high-integrity litigation section cannot be produced under those constraints.

What is the Orange Book status of glycoside hydrolase inhibitors?

Orange Book status is drug-specific. The MeSH class label is not enough to identify the specific NDA/BLA products, listed patents, expiration dates, or regulatory exclusivity codes required for an Orange Book status table.

When do glycoside hydrolase inhibitors lose exclusivity (patent expiration dates and market launch scenarios)?

Launch scenarios depend on the final expiration of the last Orange Book-listed patent (and any applicable exclusivity) and on whether any Paragraph IV settlement or court injunction controls launch.

A complete timeline needs product identification and the corresponding patent expiration and listed exclusivity end dates. These are not present in the prompt, so a correct, date-anchored exclusivity timeline cannot be generated.

Regulatory question: how FDA approvals change patent and market exclusivity for glycoside hydrolase inhibitors?

FDA approval details drive exclusivity type and patent listing behavior:

• Orphan drug exclusivity can extend market protection independent of patent term.
• Reference product selection affects data exclusivity.
• 505(b)(2) vs 505(b)(1) vs ANDA affects whether relevant patents are required to be listed and how Paragraph IV can be triggered.

A regulatory mapping cannot be produced without the specific drug product set and FDA approval pathways.

Commercial question: how much revenue is exposed to patent expiry in glycoside hydrolase inhibitors?

Revenue exposure is determined by:

• each product’s revenue (US and ex-US share),
• patient access and payer coverage,
• and expected erosion speed post-generic entry.

A revenue exposure analysis requires drug-specific commercial data and cannot be built from the MeSH class alone.

Technical question: what manufacturing and IP barriers slow down generic glycoside hydrolase inhibitors?

Key development barriers in this class typically include:

• solid-state control (polymorph selection, moisture sensitivity),
• API impurity profile control tied to claimed synthesis steps,
• CMC comparability that affects FDA approval timelines,
• formulation stability that increases time-to-validate.

These are generalized technical patterns; a drug-specific barrier assessment requires formulation/manufacturing disclosures from granted patents and ANDA/CMC summaries, which are not provided.

---

Key Takeaways

• Patent estates for glycoside hydrolase inhibitors usually split into active ingredient, formulation/solid-state, process, and method-of-use claims.
• Exclusivity timing is a two-layer problem: regulatory exclusivity and patent term.
• Formulation and process patents are frequent practical blockers even when active ingredient patents expire.
• Generic risk in this class is driven by whether Orange Book listing is dense and whether there are credible design-around paths.
• A litigation, Orange Book, and date-specific exclusivity roadmap cannot be stated without the specific drug products in scope.

---

FAQs

1. How do polymorph-specific patents affect ANDA approval for oral glycosidase inhibitors?
2. What role does orphan drug exclusivity play in delaying generic entry for glycoside hydrolase inhibitor drugs?
3. When do formulation patents typically expire relative to composition-of-matter patents in lysosomal storage disorder small-molecule inhibitors?
4. How do settlements in Hatch-Waxman cases determine at-risk launches for glycoside hydrolase inhibitors?
5. What CMC elements most often cause delays for generic development of enzyme inhibitor solid oral dosage forms?

---

References

No sources are cited because the prompt does not provide any specific drug names, NDA/BLA identifiers, patent numbers, or litigation dockets to support accurate, inline citation.